Skip to content

Revenue at other companies

Henry Schein logo
Henry ScheinHSIC
$3.37B+6.3%
CSX logo
CSXCSX
$3.48B+1.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$246.09M+87.0%
SBA Communications logo
SBA CommunicationsSBAC
$47.29M-1.6%
Loar Holdings logo
Loar HoldingsLOAR
$9.7M+48.1%
Armstrong World Industries logo
Armstrong World IndustriesAWI
$382.9M+12.8%

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's revenue?
Kymera Therapeutics (KYMR) reported revenue of $34.37M in Q1 2026.
How has Kymera Therapeutics's revenue changed year-over-year?
Kymera Therapeutics's revenue increased by 55.5% year-over-year, from $22.1M to $34.37M.
What is the long-term trend for Kymera Therapeutics's revenue?
Over 4 years (2021 to 2025), Kymera Therapeutics's revenue has grown at a -14.3% compound annual growth rate (CAGR), from $72.83M to $39.21M.